NASDAQ$NPCE

Neuropace Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

NeuroPace reported Q4 2024 revenue of $21.5M.

For Q4 2024, NeuroPace reported Revenue was $21.5M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $21.5M for Q4 2024.
  • MD&A highlights operating priorities, liquidity, and sector risks.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$21.5M

Previous: $18M+19.4%
EPS (adj)

-$0.18

Previous: -$0.23+21.7%
Gross Profit Margin

75.4%

Previous: 75.2%+0.3%
Adjusted EBITDA

-$1M

No prior period
RNS Gross Margin

80.1%

No prior period
Capital Expenditures

-$39K

Previous: $32K-221.9%
Net Income

-$5.25M

Previous: -$6.2M+15.3%
Operating Income

-$3.65M

Previous: -$5.05M+27.7%
Gross Profit

$16.2M

Previous: $13.5M+19.5%
R&D Expense

$6.05M

Previous: $5.38M+12.5%

Revenue & EPS history

Neuropace · Revenue · Quarterly

$21.5M

Q4 2024+19.4%vs Q4 2023
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

Neuropace · $1.6M total across 1 segment · Q4 2022

  • DIXI Medical
    $1.6M

Forward guidance

Outlook emphasizes clinical milestones, cash runway, and R&D spend.

Tailwinds

  • Pipeline progress and partnership optionality.
  • Balance-sheet flexibility where noted.

Headwinds

  • Operating losses until commercialization.
  • Trial, regulatory, and financing risks.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-0.7%

Avg return

Earnings day

-1.0%

Avg return

5 days after

-0.0%

Avg return

30 days after

50%

12 / 24 earnings

Positive

+37.4%

Q3 2025

Best reaction

-40.1%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.6%-1.8%+0.8%
Q4 2025+1.1%+1.6%+5.9%
Q3 2025+37.4%+43.1%+74.5%
Q1 2025+21.6%+31.3%-14.5%
Q4 2024-2.4%-15.8%+2.6%
Q3 2024+25.7%+23.4%+49.9%
Q2 2024-1.9%-0.4%+4.8%
Q1 2024-40.1%-35.9%-51.4%
Q4 2023+0.8%+2.5%-8.4%
Q3 2023-1.4%+9.5%+14.6%
Q2 2023+9.8%+9.8%+103.4%
Q1 2023+1.9%-3.5%-15.4%
Q4 2022-13.3%-7.8%-1.9%
Q3 2022-9.9%-17.6%-29.6%
Q2 2022-3.5%-10.2%-26.6%
Q1 2022+1.2%-3.6%-3.8%
Q4 2021-0.9%-7.7%-1.2%
Q3 2020-15.2%-22.2%-47.7%
Q3 2021-15.2%-22.2%-47.7%
Q2 2021-7.6%-10.7%-8.0%
Q2 2020-7.6%-10.7%-8.0%
Q1 2020+0.8%+8.7%+2.2%
Q1 2021+0.8%+8.7%+2.2%
Q4 2020+0.8%+8.7%+2.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro